Additional limitations are the fact that with the tamoxifen-induced Col1a2-CreERT2 transgene we achieved a marked and significant inhibition but not a full inactivation of the GC-B gene in fibroblasts, and that this inhibition presumably was not restricted to the CF population but involves fibroblasts from other organs. The gene discussed is NPR2; the disease is cystic fibrosis.